B-vaxx - a sleeper surprise?, page-26

Hey Dave ( @davybabyk )

Yes, agree with you AGAIN.

The ability of B-cell and T-cell vaccines to tap into ‘immunologic memory’ is something we will soon heara lot about in regard to IMU. I suspect, when its time, LC will unpack thispotential a bit more for shareholders.

Hey @sorest2016

I understand that you feel that4.5 years is a long time (‘over the top’ in your words) to prove 'lifeextension'. It is a long time, but in my experience with Bio-Techs there aremany, many trials that run much longer.

In my opinion IMU are gathering alot more info around the mechanisms of B-VAXX, in addition to just proving ‘lifeextension’. It would seem they already know that B-VAXX combines powerfullywith PD1-VAXX. I also suspect we will hear much more about this ‘combined treatment’in the future.

Unlike many Bio-Techs, IMU is actually gathering data ‘at light speed’ as Cpt Kirk would say. The positive signals gathered during the PD-VAXX Phase 1 is just one example.

The news is coming, and it may be coming a lot faster than some investors realise. As I have said before – hold on to your hats. I believe this is going to be an amazing ride.

All just my opinion of course.